<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086458</url>
  </required_header>
  <id_info>
    <org_study_id>SHSYEK-001</org_study_id>
    <nct_id>NCT05086458</nct_id>
  </id_info>
  <brief_title>Impact of Probiotics Supplement on the Gut Microbiota in Caesarean-born Infants</brief_title>
  <official_title>Impact of Probiotics Supplement on the Gut Microbiota in Caesarean-born Infants: an Open-label Single-center Randomized Parallel Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of probiotics on the gut microbiota of&#xD;
      infants born by cesarean section.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to examine the impact of probiotics administration on the gut microbiota of&#xD;
      infants born by cesarean section. Birth,14 days and 42 days data will be collected and put&#xD;
      into analysis to provide some suggestions on the probiotics use in the clinical for the&#xD;
      infants born by cesarean section.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2021</start_date>
  <completion_date type="Anticipated">October 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in gut microbiota at 42 days between no intervention group and experimental group.</measure>
    <time_frame>42 days</time_frame>
    <description>Study the microbiota change of stool samples at 42 days between no intervention group and experimental group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in gut microbiota at 14 days between no intervention and experimental group.</measure>
    <time_frame>14 days</time_frame>
    <description>Study the microbiota change of stool samples 14 days between no intervention group and experimental group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiota at birth between no intervention and experimental group.</measure>
    <time_frame>birth</time_frame>
    <description>Study the microbiota change of stool samples at birth between no intervention group and experimental group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gut Microbiota</condition>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>the patients in this arm will not receive probiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietary Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotics</intervention_name>
    <description>probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis</description>
    <arm_group_label>Dietary Supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Neonates born by caesarean section&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gestational weeks &lt;37 Birth weight &lt;2500g or â‰¥4000g History of asphyxia anoxia at&#xD;
             birth With congenital metabolic diseases or hereditary diseases With gastrointestinal&#xD;
             diseases With infectious diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>42 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huanlong Qin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai 10th People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rong Yang, MD</last_name>
    <phone>13321917107</phone>
    <email>yangrongtongji@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Zhong</last_name>
    <phone>13701806709</phone>
    <email>zhonghuiunique@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rong Yang</name>
      <address>
        <city>Shanghai</city>
        <zip>20072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Yang, MD</last_name>
      <phone>13321917107</phone>
      <email>yangrongtongji@163.com</email>
    </contact>
    <investigator>
      <last_name>Huanlong Qin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Huanlong Qin</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>gut microbiota</keyword>
  <keyword>probiotics</keyword>
  <keyword>infant</keyword>
  <keyword>cesarean section</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

